FridayMay 31, 2024 9:45 am

GEMXX Corp. (GEMZ) Enters Alliance with Latin Energy Partners to Advance Groundbreaking Developments in Oil Exploration in Latin America

GEMXX recently entered a significant partnership with Latin Energy Partners that has seen the two companies define terms to jointly drill four test wells in a promising geologic formation in a Latin American country The partnership is part of GEMXX’s plans to strategically expand its current successful business model, diversifying its business portfolio, and exploring new underground resource opportunities Latin America has large tracts and regions of under-explored sedimentary basins which hold significant oil and gas resources potential Preliminary explorations in the two basins suggest potential for more than 1 billion barrels each of recoverable oil, positioning GEMXX and Latin…

Continue Reading

TuesdayMay 28, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024

Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavailability, usually as little as 0.8% Lexaria, through its study, looks to demonstrate the effectiveness of its DehydraTECH(TM) technology in improving GLP-1’s bioavailability, opening up a vast worldwide market Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 (https://ibn.fm/74Pee). This follows the recent…

Continue Reading

TuesdayMay 21, 2024 10:30 am

GEMXX Corp. (GEMZ) Expands to Oil and Gas Exploration Ventures, Creating New Strategic Partnerships in Industry

In an expansion of operations, GEMXX plans to finance the exploration of extensive oil reserves, specifically targeting giant fields with reserves of 500 million barrels and super-giant fields with over 3 billion barrels located primarily in Latin America By leveraging a comprehensive network in the oil and gas sector, GEMXX plans to develop strong strategic partnerships and secure funding to propel exploration efforts quickly GEMXX has also announced Richard Clowater as the new Chief Executive Officer and Chairman of the Board, and the appointment of Deane Preston to its Board of Directors, effective May 15, 2024 GEMXX (OTC: GEMZ), an…

Continue Reading

TuesdayMay 14, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation

Lexaria, a global innovator in drug delivery platforms, just announced its newest relationship with the National Research Council of Canada (“NRC”) Specific molecular characteristics of the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, processed with Lexaria’s patented DehydraTECH(TM) technology, will be evaluated Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood compared to Rybelsus(R). This has potential for increased weight-loss and diabetic control Lexaria’s management is confident that this partnership will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a…

Continue Reading

ThursdayMay 09, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance

Lexaria has entered an agreement wherein an existing accredited investor has exercised all their warrants to purchase shares The company has received $4.7 million from this undertaking, prior to deducting estimated offering expenses Proceeds fully fund Lexaria’s entire planned 2024 GLP-1 R&D program, leaving additional excess capital for general purposes Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its entry into a warrant exercise agreement with an existing accredited investor to exercise in full certain existing warrants initially issued in October 2023 and February 2024. The warrants will be exercised at $0.97 and $2.185 per…

Continue Reading

TuesdayMay 07, 2024 8:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology

Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024 GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings…

Continue Reading

Contact us: (310) 299-1717